10:14 EDT Gilead (GILD) down 2% to $111.14 after FDA placed hold on some HIV trials
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating
- Gilead Sciences’ Oncology Advancements: Trodelvy’s Potential to Boost Stock Value
- Gilead Sciences: Promising Pipeline and Strategic Advancements Justify Buy Rating
- Gilead Sciences: Buy Rating Driven by Promising HIV Treatment Pipeline and Strategic Growth Prospects
- Gilead Sciences: Buy Rating Affirmed on Promising Oncology Pipeline and Trodelvy’s Potential as New Standard of Care